The authors wish to make the following corrections to this paper []: On page 6, the curve in Figure 5a was switched with Figure 7c on Page 7. Thus, Figure 5 should be replaced with the following figure (Figure 1), and Figure 7 with the following figure (Figure 2).
Figure 1.
Peripheral cannabinoid receptor 1 (CB1R) antagonist increased oxygen consumption rate (OCR). 3T3-L1 adipocytes were treated with AM6545, rimonabant (RIM), and isoproterenol (ISO) at 4 and 48 h. OCR was measured in basal conditions or in response to sequential treatment with 2 oligomycin, 0.75 FFCP (respiratory chain uncoupler), and 1 µM rotenone/antimycin A (inhibitor of respiratory chain complex I and complex III) using the Seahorse XF-24 analyzer. (A) Mitochondrial respiration curves at 4 h after treatment. (B) Parameters calculated from the tracing at 4 h after treatment. (C) Mitochondrial respiration curves 48 h after treatment. (D) Parameters calculated from the OCR at 48 h after treatment. Data on graphs are presented as the mean ± standard error of mean (SEM) of 4 independent rounds of the cells; * p < 0.05 vs. control, ** p < 0.01 vs. control.
Figure 2.
Peripheral cannabinoid receptor 1 (CB1R) antagonist increased oxygen consumption rate (OCR) inhibited by lipolysis blocker. 3T3-L1 adipocytes were treated with AM6545 and rimonabant (RIM) with and without Atglinstatin, and isoproterenol (ISO) at 4 and 48 h. OCR was measured in basal conditions or in response to sequential treatment with 2 µM oligomycin, 0.75 µM FFCP (respiratory chain uncoupler), and 1 µM rotenone/antimycin A (inhibitor of respiratory chain complex I and complex III) using the Seahorse XF-24 analyzer. (A) Mitochondrial respiration tracing using Seahorse at 4 h after treatment. (B) Parameters calculated from the tracing at 4 h after treatment. (C) Mitochondrial respiration tracing 48 h after treatment. (D) Parameters calculated from the tracing at 48 h after treatment. Data on graphs are presented as the mean ± standard deviation (SD) of 4 independent rounds of the cells; * p < 0.05 vs. control, ** p < 0.01 vs. control.
The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. The original article has been updated.
Conflicts of Interest
The authors declare no conflict of interest.
Reference
- Paszkiewicz, R.L.; Bergman, R.N.; Santos, R.S.; Frank, A.P.; Woolcott, O.O.; Iyer, M.S.; Stefanovski, D.; Clegg, D.J.; Kabir, M. A Peripheral CB1R Antagonist Increases Lipolysis, Oxygen Consumption Rate, and Markers of Beiging in 3T3-L1 Adipocytes Similar to RIM, Suggesting that Central Effects Can Be Avoided. Int. J. Mol. Sci. 2020, 21, 6639. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).